Our position on the NIMH remains that it has no legal basis
for existing. It needs to be de-funded, everyone working there fired, and the
buildings sold at public auction.
The US National Institute of Mental Health has appointed
psychiatrist Sarah Hollingsworth Lisanby to the role of director of its
Division of Translational Research. Lisanby holds "key leadership"
positions in organizations that promote the use of electro-convulsive therapy,
noted an NIMH press release, and she will now oversee $400 million in research funding
into the biological causes and treatments of mental illnesses.
Lisanby is President for the Association for Convulsive
Therapy/International Society of Neurostimulation and the International Society
for Transcranial Stimulation, and is also Chair of the American Psychiatric
Association Task Force to Revise the Practice on Electroconvulsive Therapy
(ECT), stated the press release. It does not mention that in 2008 the FDA cited
Lisanby for numerous ethical violations and safety compliance lapses in a clinical
trial she was leading -- the trial involved a "device" for which
identifying information is censored on the FDA website. In 2011, Lisanby
testified during FDA hearings that she believed safety restrictions on
electroshock devices should be loosened.
In her new role with NIMH, Lisanby will "help set a
national agenda for research on mental illness," stated the press release.
Inspections,
Compliance, Enforcement, and Criminal Investigations: Lisanby, Sarah H., M.D.
6-Oct-08 (Food and Drug Administration, October 6, 2008)
Duke
University psychiatrist Sarah Hollingsworth Lisanby, M.D. will join NIMH in
Fall 2015 (NIMH press release, March 4, 2015)
--Rob Wipond,
News Editor
This entry was posted in Featured News, In the News and
tagged Google News.
Bookmark the permalink.
RELATED POSTS
Thank You Mr Wipond and MIA.
No comments:
Post a Comment